Tag: antigens
Cell Therapy Takes Aim at Deadly Brain Tumors in Two Clinical Trials
When my uncle was diagnosed with glioblastoma, I knew he was on borrowed time.The deadliest form of brain cancer, it rapidly spreads through the...
Top News
Breaking News
A biotechnology company dedicated to developing BsAb-based therapies in China, YZY Biopharma Officially Listed on Main Board of SEHK
Hong Kong, Sept 25, 2023 - (ACN Newswire) - Wuhan YZY Biopharma Co., Ltd. ("YZY Biopharma" or the "Company", together with its subsidiaries, the...
Aichi Cancer Center and NEC Develop an Efficient Method for Identifying Lung Cancer Antigens and Antigen-Specific T Cells
TOKYO, Aug 08, 2023 - (JCN Newswire) - Aichi Cancer Center and NEC Corporation's research group with Gifu University, Toyama University and Kitasato University...
‘Living Drug’ CAR T Is Taking on Some of Humanity’s Worst Medical Scourges
Ask a cancer researcher what the breakthrough treatment of the decade is, and they’ll tell you CAR T takes the crown.The therapy genetically engineers...
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
HEIDLEBERG, Germany, Apr 4, 2023 - (ACN Newswire) - BioMed X, an independent biomedical research institute, announces the start of its new research project - "New Strategies to...
Fate Therapeutics, Inc. (FATE) Shareholder Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Fate Therapeutics, Inc.
SAN DIEGO–(BUSINESS WIRE)–$FATE #FATE—The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or...
Scientists develop AI algorithms to hunt for cancer-fighting antibodies
AI is helping scientists discover new antibodies that could trigger our own immune systems into destroying cancer cells.
The immune system produces antibodies, specialised proteins...
NOTICE: Investors in Fate Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – FATE
SAN DIEGO–(BUSINESS WIRE)–Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fate Therapeutics, Inc. (NASDAQ: FATE) securities between April 2, 2020...
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Fate Therapeutics, Inc. (FATE)
SAN DIEGO–(BUSINESS WIRE)–$FATE #FATE—The Class: Robbins LLP informs shareholders that a shareholder filed a class action on behalf of all investors who purchased or...
SinoMab Awarded the “Most Valuable Pharmaceutical and Medical Company” in the Selection of the “7th Hong Kong Golden Stocks Awards”
HONG KONG, Dec 19, 2022 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based...
PDC*line Pharma Presents First Immunological Results From Phase I/II Trial With PDC*lung01 at ESMO-IO 2022
Treatment with PDC*lung01 induces anti-tumor immune response in significant number of patients which appears to be enhanced by combination with pembrolizumab
LIÈGE, Belgium, & GRENOBLE,...
IMV Shareholders Approve Reverse Stock Split at 88%
IMV’s common shares expected to begin trading on a split-adjusted basis on December 13, 2022
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$IMV #DeliveryPlatform–IMV Inc. (the...
CAR-T Cell Therapy Global Market Report 2022: Rapid Pace of Innovation Spurring Investment and Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “CAR-T Cell Therapy Market by Target Indications, Target Antigens, Key Players and Key Geographies – Global Forecast 2022-2035” report has been added...
